# PERCEIVE-II (extended validation for gynaecological cancers)

Source: https://onco.cc/trials/perceive-2/  
OnCo record `perceive-2` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The larger follow-on Chinese study validating a blood test for several gynaecological cancers.

## Summary

PERCEIVE-II (NCT06001099) is an observational study sponsored by Fudan University with Guangzhou Burning Rock Dx Co., Ltd. It validates combined methylation, mutation and microRNA assays for early detection of gynaecological cancers.

The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 29 September 2023), with an estimated 2,935 participants, a start on 22 February 2023 and primary completion expected on 30 June 2024.

## Fields

- Kind: Trial
- Last checked: 2026-10-29
- Also known as: PERCEIVE-II
- Registry id: NCT06001099
- Phase: observational
- Setting: Women with gynaecological cancers and healthy women at Fudan University, extending the validation of a multi-omic blood test
- Sponsor: Fudan University with Guangzhou Burning Rock Dx Co., Ltd.
- Enrolled: 2935

## Sources

- ClinicalTrials.gov NCT06001099: https://clinicaltrials.gov/study/NCT06001099

## Connected records

- trials: [PERCEIVE-I (multi-omic blood test for gynaecological cancers)](https://onco.cc/trials/perceive-1/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Burning Rock Biotech](https://onco.cc/companies/burning-rock/)

---
JSON: https://onco.cc/api/v1/entities/perceive-2.json